key: cord-0909912-dmkc6tfd
authors: Koupaei, Maryam; Mohamadi, Mohamad Hosein; Yashmi, Ilya; Shahabi, Amir Hossein; Shabani, Amir Hosein; Heidary, Mohsen; Khoshnood, Saeed
title: Clinical manifestations, treatment options, and comorbidities in COVID‐19 relapse patients: A systematic review
date: 2022-04-08
journal: J Clin Lab Anal
DOI: 10.1002/jcla.24402
sha: c852d5258cc4461ee17a83269a25b998cb3f5f2d
doc_id: 909912
cord_uid: dmkc6tfd

INTRODUCTION: Interest revolving around coronavirus disease 2019 (COVID‐19) reinfection is escalating rapidly. By definition, reinfection denotes severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), PCR redetection, and COVID‐19 recurrence within three months of the initial symptoms. The main aim of the current systematic review was to evaluate the features of COVID‐19 relapse patients. MATERIALS AND METHODS: For this study, we used a string of terms developed by a skilled librarian and through a systematical search in PubMed, Web of Science, and Embase for eligible studies. Clinical surveys of any type were included from January 2019 to March 2021. Eligible studies consisted of two positive assessments separated by a negative result via RT‐PCR. RESULTS: Fifty‐four studies included 207 cases of COVID‐19 reinfection. Children were less likely to have COVID‐19 relapse. However, the most patients were in the age group of 20–40 years. Asthenia (66.6%), headache (66.6%), and cough (54.7%) were prevalent symptoms in the first SARS‐CoV‐2 infection. Asthenia (62.9%), myalgia (62.9%), and headache (61.1%) were most frequent in the second one. The most common treatment options used in first COVID‐19 infection were lopinavir/ritonavir (80%), oxygen support (69.2%), and oseltamivir (66.6). However, for the treatment of second infection, mostly antibiotics (100%), dexamethasone (100%), and remdesivir (80%) were used. In addition, obesity (32.5%), kidney failure (30.7%), and hypertension (30.1%) were the most common comorbidities. Unfortunately, approximately 4.5% of patients died. CONCLUSION: We found the potency of COVID‐19 recurrence as an outstanding issue. This feature should be regarded in the COVID‐19 management. Furthermore, the first and second COVID‐19 are similar in clinical features. For clinically practical comparison of the symptoms severity between two epochs of infection, uniform data of both are required. We suggest that future studies undertake a homogenous approach to establish the clinical patterns of the reinfection phenomena.

Lancman et al. 35 USA OR "severe acute respiratory syndrome coronavirus 2" OR "novel coronavirus" OR "SARS-CoV-2" OR "nCoV disease" OR "SARS2" OR "2019-nCoV" OR "coronavirus disease-19" OR "coronavirus disease 2019" OR "2019 novel coronavirus" OR "Wuhan coronavirus" OR "Wuhan seafood market pneumonia virus" OR "Wuhan pneumonia"). There was no limitation on language, location, and type of studies.

All the studies reported the reactivation or second infection of COVID-19 were considered in the search. Total records were retrieved and entered into EndNote X9 software (Thomson Reuters).

Following duplicate exclusion, a three-stage screening was carried out to exploit the eligible studies based on title, abstract, and full text. The whole eligible studies reported the patients who were recovered from primary infection, but then developed a secondary same studies, congress abstracts, reviews, systematic reviews and meta-analysis, cellular and molecular studies, and animal studies. All types of manifestations and treatments were regarded without any restriction, and there was no limitation on comorbidities and underlying disorders.

The following data were acquired from each article: first author's name, location, publication time, type of study, number of relapsed patients, age, gender, interval between two infections, clinical manifestations, treatment, relative status, comorbidities, and outcome. Two investigators independently extracted the data from full text of 54 included studies. Inconsistencies between reviewers

were resolved by consensus. The retrieved data are represented in Table 1 .

The critical appraisal checklist provided by the Joanna Briggs 

The search strategy yielded 1807 studies from three databases. Thirteen studies were originated from Europe, 11 from the USA, 9

from China, and 6 from Brazil. These articles reported a total number of 207 patients who developed the second infection of coronavirus after a recovery, which was confirmed by a negative RT-PCR test.

Forty-six studies reported the clinical features in the first infection;

however, seven articles declared no symptoms. Only one study unrecorded the clinical features in the first infection. In addition, 42

investigations implied the medication and intervention.

In the second phase of infection, 43 articles reported the clinical manifestations, seven articles stated no sign, and four articles did not list any symptoms. Also, 37 studies reported specifically the 

Considering the studies included, we reviewed 207 patients pre- 

Some clinical signs were most frequent between the two infections, were used (Table 2 ).

The evaluating comorbidities and underlying conditions can enlighten some aspects of COVID-19. Based on the extracted data, a number of underlying diseases and conditions had a notable frequency. Obesity was highlighted as a condition in 32.5% of patients by 15 articles, whereas 22 studies stated diabetes with an overall prevalence of 15.15%. Hypertension and heart failure were reported to be 30.16% and 26.09% in 24 and 17 articles, respectively. Neurodegenerative disorders such as Alzheimer's (9.52%) and

Parkinson's (9.52%) diseases were found as comorbidities ( Table 2) .

However, evidence established an association between these types of comorbidities and COVID-19; further investigations could clarify the detailed mechanisms of these relations.

To prevent reinfection or reactivation, four criteria can be consid- Several factors influencing reinfection, including the initial load of the virus and the type of genome, are virus-dependent. 16 The average duration of SARS-CoV-2 shedding is 20 days, which in some cases is 37 days. 17 

factors, such as the level of the individual's immune system or the accuracy of the tests, that affect this time period. Perhaps, the reason for the recurrence of the disease 7-14 days after discharge from the hospital is that the virus is still hidden in exosomes or extracellular vesicles and resumes activity after a period of "silences". 14 In this study, RT-PCR was a necessary inclusion criterion. Thus, patients with only a serologic diagnosis test, without a nasopharyngeal swab RT-PCR were excluded. RT-PCR is the gold standard for diagnosing SARS-CoV-2; however, this test has low sensitivity due to test error or insufficient sample size. 19 The accuracy of RT-PCR is 97%, 20 and the occurrence of false negatives in PCR of SARS-CoV-2 has been reported to be 30%, 21 which in some cases increases due to sampling error. 20 One of the reasons for the error in RT-PCR is the prolonged conversion of nucleic acid, which causes recurrence or "turn positive". 22 In the early stages of infection, the SARS-CoV-2 is readily detected in the upper respiratory tract. As the disease progresses, the virus appears in the lower respiratory tract and other organs such as the intestines and blood. 23 Therefore, it is impossible to identify SARS-CoV-2 in the throat, and some patients may have positive CT scan, despite the negative RT-PCR. 24 Incorrect sampling is another reason for recurrence in improved individuals, 14 although it is unlikely to happen due to the use of devices such as gloves, masks, and caps. 25 As Although studies have shown that underlying conditions cause the severity of COVID-19 disease, but how each of these factors contribute to reinfection should be examined by designing new studies determining these effects separately or in combination. 28, 29 The clinical features of patients with reinfection are similar to those of primary infection. The presence of asymptomatic patients among reactivated patients caused the recurrence of the asymptomatic contamination or infection with few symptoms. 14, 16 In an earlier study, rhesus macaques became reinfected after recovery, without showing any symptoms. This finding highlights the need for strict protection from SARS-CoV-2 and its control, to hider the development of this severe disease. 30 The second time of infection severity is varied; some cases show mild, and some others indicate more severe symptoms. 10 In a former study, 46.03% of patients had a worse condition, and 39.68% had a better condition in the second than the first infection. One of the reasons for the deteri- In a study performed by Okhuese, the proportion of infected population will continue to grow in the world if unvaccinated. At the same time, the rate of recovery will continue slowly. In other words, in this situation, the mortality rate can be determined based on the ratio of infection to recovery rate. The rate of reinfection with clinical clearance of the virus from the improved population decreases to zero over time. 32 Contrary to the results achieved in Okhuese's study, 33 despite the high prevalence of SARS-CoV-2, the rate of reinfection is still high. Therefore, more experimental and laboratory studies are needed to determine the cause of reinfection and its frequency. Of note, reinfection differs from reactivation.

Reinfection is caused by different variants of SARS-CoV-2 virus, but reinfection occurs with the same strain. The only way to discriminate the reinfection and reactivation is by sequencing and molecular techniques. 34 Regrettably, the first two actions happen only in 5%-10%. 10 Designing studies to sequence the virus genome in the first and second infections is highly recommended. In this way, the cause of COVID-19 recurrence is clarified, and its prevalence in the community is determined.

A number of limitations can be considered in this study. The first is the small number of original articles and short communication. The second is related to case series and case reports studies, which lack sufficient and accurate information on patients and are often reported descriptively. Therefore, accurate meta-analysis calculations were impossible in this study.

The present study represents a large number of COVID-19 reactivation over different countries. Overall, the recurrence of COVID-19 in 

The authors declare that they have no competing interests. 

Not applicable.

Not applicable.

All the data in this review are included in the study.

https://orcid.org/0000-0002-9839-5017

Another decade, another coronavirus

Coronavirus disease 2019: what we know

Coronavirus variants are spreading in India-what scientists know so far

The global threat of the coronavirus variants

A review of coronavirus disease-2019 (COVID-19)

Is novel coronavirus 2019 reinfection possible? Interpreting dynamic SARS-CoV-2 test results

COVID-19 reinfection

14% of Recovered Covid-19 Patients in Guangdong Tested Positive Again

COVID-19: is reinfection a threat or not? Iran J Publ Health

What we know about covid-19 reinfection so far

A case of COVID-19 reinfection in the UK

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement

The Joanna Briggs Institute Critical Appraisal Tools for Use in JBI Systematic Reviews Checklist for Analytical Cross Sectional Studies

On the potential role of exosomes in the COVID-19 reinfection/reactivation opportunity

Immune response variables and viral mutations impact on COVID-19 reinfection and relapse

Clinical characteristics of severe acute respiratory syndrome coronavirus 2 reactivation

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Prolonged SARS-CoV-2 RNA shedding: not a rare phenomenon

Eleven faces of coronavirus disease 2019

Chest CT for typical 2019-nCoV pneumonia: relationship to negative RT-PCR testing

Detection of SARS-CoV-2 in different types of clinical specimens

False negative of RT-PCR and prolonged nucleic acid conversion in COVID-19: rather than recurrence

Molecular and serological investigation of 2019-nCoV infected patients: implication of multiple shedding routes

Sensitivity of chest CT for COVID-19: comparison to RT-PCR

Efficacy of serology testing in predicting reinfection in patients with SARS-CoV-2

PCR assays turned positive in 25 discharged COVID-19 patients

Virological assessment of hospitalized patients with COVID-2019

COVID-19 in HIV-positive patients: a systematic review of case reports and case series

Clinical characteristics, diagnosis, treatment, and mortality rate of TB/COVID-19 coinfectetd patients: a systematic review

Reinfection could not occur in SARS-CoV-2 infected rhesus macaques

Dengue hemorrhagic fever: two infections and antibody dependent enhancement, a brief history and personal memoir

Estimation of the probability of reinfection with COVID-19 by the susceptible-exposed-infectious-removedundetectable-susceptible model

Covid-19: Hong Kong Scientists Report First Confirmed Case of Reinfection

Severe COVID-19 virus reactivation following treatment for B cell acute lymphoblastic leukemia

Re-evaluation of retested nucleic acidpositive cases in recovered COVID-19 patients: report from a designated transfer hospital in Chongqing

Reinfection in a healthcare worker with COVID-19 in a hospital in North India

Symptomatic SARS-CoV-2 re-infection of a health care worker in a Belgian nosocomial outbreak despite primary neutralizing antibody response. medRxiv

Severe, symptomatic reinfection in a patient with COVID-19

Second COVID-19 infection in a patient with multiple myeloma in Brazil-reinfection or reactivation?

Recurrent pneumonia in a patient with new coronavirus infection after discharge from hospital for insufficient antibody production: a case report

Symptomatic recurrence of SARS-CoV-2 infection in healthcare workers recovered from COVID-19

Recurrent coronavirus diseases 19 (COVID-19): a different presentation from the first episode

Reinfection of severe acute respiratory syndrome coronavirus 2 in an immunocompromised patient: a case report

Reinfection of COVID-19 in Pakistan. A first case report

Symptomatic relapse and long-term sequelae of COVID-19 in a previously healthy 30-year-old man

Second episode of COVID-19 in health professionals: report of two cases

The first case of COVID-19 reinfection in Duhok City, Kurdistan Region of Iraq. A case report

Reinfection or reactivation of coronavirus-19 in patients with hematologic malignancies: case report series

Repeated COVID-19 relapse during post-discharge surveillance with viral shedding lasting for 67 days in a recovered patient infected with SARS-CoV-2

Recurrent SARS-CoV-2 infection resulting in acute respiratory distress syndrome and development of pulmonary hypertension: a case report

Recurrent COVID-19 including evidence of reinfection and enhanced severity in thirty Brazilian healthcare workers

Reinfection with SARS-CoV-2 and Failure of Humoral Immunity: a case report

A case report of possible novel coronavirus 2019 reinfection

Late reactivation of SARS-CoV-2: a case report

A case of SARS-CoV-2 reinfection in a patient with obstructive sleep apnea managed with telemedicine

A case presentation for positive SARS-CoV-2 RNA recurrence in a patient with a history of type 2 diabetes that had recovered from severe COVID-19

A first probable case of SARS-CoV-2 reinfection in Colombia

A new positive SARS-CoV-2 test months after severe COVID-19 illness: reinfection or intermittent viral shedding?

A patient with asymptomatic SARS-CoV-2 infection who presented 86 days later with COVID-19 pneumonia possibly due to reinfection with SARS-CoV-2

Are SARS-CoV-2 reinfection and Covid-19 recurrence possible? A case report from Brazil

Asymptomatic reinfection in two healthcare workers from India with genetically distinct SARS-CoV-2

Usefulness of blood parameters for preliminary diagnosis of brucellosis

Case report: recurrence of positive SARS-CoV-2 results in patients recovered from COVID-19

Case report: a COVID-19 reactivation case

Case reports of COVID 19 recurrence

Confirmed reinfection with SARS-CoV-2 variant VOC-202012/01

Coronavirus disease 2019 reinfection: first report from Turkey

A case of SARS-CoV-2 reinfection in Ecuador

Fatal relapse of COVID-19 after recovery? A case report of an older Italian patient

Viral RNA level, serum antibody responses, and transmission risk in recovered COVID-19 patients with recurrent positive SARS-CoV-2 RNA test results: a population-based observational cohort study

Prevalence and outcomes of repositive nucleic acid tests in discharged COVID-19 patients

Genomic evidence for reinfection with SARS-CoV-2: a case study

Genomic Evidence of a Sars-Cov-2 Reinfection Case With E484K Spike Mutation in Brazil

Reactivation of COVID-19 pneumonia: a report of two cases

Reactivation of SARS-CoV-2 after asymptomatic infection while on high-dose corticosteroids. Case report

Recurrence of COVID-19 after recovery? A case series in health care workers

Recurrence of COVID-19 Documented with RT-PCR

Recurrent recurrence of positive SARS-CoV-2 RNA in a COVID-19 patient

Recurrence of SARS-CoV-2 nucleic acid positive test in patients with COVID-19: a report of two cases

Recurrence or relapse of COVID-19 in older patients: a description of three cases

COVID-19 infection recurrence presenting with meningoencephalitis

Asymptomatic reactivation of SARS-CoV-2 in a child with neuroblastoma characterised by whole genome sequencing

Case report: a recovered SARS CoV-2 patient protected from reinfection

Recurrence of SARS-CoV-2 infection with a more severe case after mild COVID-19, reversion of RT-qPCR for positive and late antibody response: case report

COVID-19 in a patient with endstage renal disease on chronic in-center hemodialysis after evidence of SARS-CoV-2 IgG antibodies. Reinfection or inaccuracy of antibody testing

Evidence of severe acute respiratory syndrome coronavirus 2 reinfection after recovery from mild coronavirus disease 2019